Jefferies Upgrades Certara to Buy, Announces $31 Price Target
Jefferies analyst David Windley upgrades Certara (NASDAQ:CERT) from Hold to Buy and announces $31 price target.
54 Biggest Movers From Yesterday
Gainers
Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the treatment of hypoplastic left heart syndrome.
44 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the treatment of hypoplastic left heart syndrome.
Certara Q3 EPS $0.07 Beats $0.06 Estimate, Sales $73.94M Beat $72.82M Estimate
Certara (NASDAQ:CERT) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.06 by 16.67 percent. This is a 250 percent increase over earnings of $0.02 per share from the same
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Certara Appoints James E. Cashman III As Chairman Of Board Of Directors
Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that James E. Cashman III, a current Board member, will be appointed Chairman of the Board of Directors, effective as of December 1, 2021.
